Brief Update on Influenza ACIP Recommendations

Carolyn B. Bridges, MD
Associate Director of Adult Immunizations
Immunization Services Division
National Center for Immunizations and Respiratory Diseases
On behalf of Dr. Lisa Grohskopf, Influenza Division

ACIP Influenza Statement for 2011–2012

- No substantive change in guidance is anticipated for the 2011–2012 season

- 2011–2012 statement to contain updated information on relevant topics (e.g., any new vaccine products, new information on vaccination in setting of egg allergy)

- Topics to be included in 2011–2012 statement will be discussed at the June 22–23, 2011 ACIP meeting

- CDC and ACIP are initiating a graded review of the influenza vaccine literature, with goal of presenting the statement in the newly adopted evidence-based format for the 2012–2013 season
Groups Recommended for Vaccination

- No changes to groups recommended for annual influenza vaccination are anticipated.
  - Annual influenza vaccination is recommended for all persons aged 6 months and older
- Groups considered at higher risk for severe illness:
  - Children <5 years, (particularly those <2); adults 65 years and older
  - Adults and children who have:
    - asthma
    - neurological and neurodevelopmental conditions
    - chronic lung disease, including asthma
    - heart disease
    - blood, endocrine, liver, kidney, and metabolic disorders
    - weakened immune systems due to disease or medication
    - people younger than 19 years old who are receiving long-term aspirin therapy
    - pregnant women
    - severely obese persons
    - Alaska Natives/American Indians

Vaccine Strain Selection for 2011–2012

- Recommended by WHO for Northern Hemisphere for 2011–2012:
  - Same strains as for 2010–2011
    - A(H1N1): A/California/7/2009–like
    - A(H3N2): A/Perth/16/2009–like
    - B: B/Brisbane/60/2008–like

- FDA Vaccine and Related Biologic Products Advisory Committee (VRBPAC) approved these strains for inclusion in the 2011–2012 US vaccine on February 25, 2012